GFR Trends with Tocilizumab Therapy for Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients: A Single-Center Experience (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1183; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Standard of care treatment with IVIG and rituximab has limited efficay. Conclusion Tocilizumab therapy stabilizes renal function in kidney transplant patients experiencing cABMR. Cessation of tocilzumab results in a decline in renal function and prolonged treatment should be considered to preserve renal function."
Clinical • Antibody-mediated Rejection • Inflammation • Transplantation
|
|
Pitchamon Inkong; Suphamai Bunnapradist; Ahad A. Qureshi; Phuong-Thu T. Pham; Supreet Sethi; Erik Lawrence Lum
|